Brazil’s CVM Orders Oncoclínicas Tender Offer for Minorities

Brazil · MARKETS

A 3-0 vote by Brazil’s securities regulator forces the Oncoclínicas tender offer long demanded by minority investors, but the final price tag is still to be defined.

Brazil’s securities regulator, the CVM, voted on Tuesday 25 August 2026 to require a tender offer for the shares of Oncoclínicas, the country’s largest private cancer-care chain, settling a dispute that had gripped the stock market for months. The board ruled by three votes to zero that asset manager Centaurus must launch an Oncoclínicas tender offer to buy out minority shareholders, reversing the regulator’s own technical staff, which had concluded in June that no offer was owed. The written vote is expected to be published on Wednesday.

A unanimous board reverses the technical staff

The three voting members of the CVM board, president Otto Lobo and directors João Accioly and Igor Muniz, sided with the minority investors who had appealed against the regulator’s technical area. Director Marina Copola had declared herself recused and did not take part, and one of the board’s five seats is vacant. The ruling overturns a June opinion by the CVM’s registration superintendency, known as the SRE, which had accepted Centaurus’s argument that it fell under an exception written into the company’s bylaws. Asset manager Latache, which leads the minority camp, and an association of investors in listed companies brought the appeal that was judged on Tuesday.

At the heart of the case is a poison-pill clause in the Oncoclínicas bylaws. It obliges any shareholder who comes to hold 15% or more of the capital after the company’s 2021 initial public offering to make an offer for the remaining shares at a premium. Minority investors argue the trigger was pulled in November 2024, when a reorganization of the Josephina funds, long managed by Goldman Sachs, transferred 104.6 million shares, about 16% of the company at the time, to the Josephina III fund linked to Centaurus. The manager contends it was the economic owner of the stake since 2018, before the IPO, and that the operation merely changed the form in which the position was held.

Price, scope and value remain open

Tuesday’s decision establishes the obligation, not the final bill. Market estimates cited by Brazilian media put a potential Oncoclínicas tender offer at around R$6.5 billion (about US$1.26 billion), assuming a price close to R$16 (about US$3.11) per share, but the CVM has not set any figure. The bylaws lay out several pricing criteria, including 120% of the highest quotation recorded by the stock over a defined 12-month window and an independent economic valuation. Some shareholders have argued for a price between R$16 and R$17 per share, a level that could still be contested in further proceedings.

The written vote, expected on Wednesday, should specify which group of shareholders will be eligible to sell into the offer. Lawyers following the case say the reference date matters as much as the price: if the obligation arose in late 2024, the offer should arguably have been made by January 2025, when the stock traded far above current levels. Oncoclínicas shares changed hands at R$1.57 (about US$0.31) as recently as Friday 21 August, after falling around 70% between January and July, which explains why the gap between the market price and any tender price is so wide.

What the Oncoclínicas tender offer means for minority shareholders

The clearest beneficiary is Latache, which became the largest individual shareholder with about 14.6% of the capital after building its position in the wake of the Banco Master collapse. Estimates suggest the manager could raise around R$1.5 billion (about US$292 million) if it tenders its full position. For smaller investors who bought shares after the stock collapsed, the Oncoclínicas tender offer represents a rare chance to exit at a premium to recent prices rather than wait for an operational turnaround at a company carrying heavy debts.

That turnaround is far from guaranteed. Oncoclínicas filed for extrajudicial recovery in July, seeking to renegotiate debts of about R$5.1 billion (about US$992 million). The company also booked a loss of R$433 million (about US$84 million) on bank certificates issued by Banco Master, the lender liquidated by the central bank last year. State lender Banco de Brasília, which received Oncoclínicas shares as part of credit recovery operations, has said it does not take part in the tender offer discussions and has no role in the company’s governance.

Arbitration and investigations run in parallel

The ruling does not end the legal fight. On Saturday 22 August, three days before the vote, Centaurus filed an arbitration claim against Latache at the Market Arbitration Chamber of B3, the São Paulo stock exchange. After the decision, the Josephina III fund said it disagreed with the board, arguing that the arbitration chamber holds exclusive jurisdiction over what it called a commercial dispute between partners of a listed company. The arbitration is confidential and, in principle, does not suspend the effects of the CVM ruling, but it could shape how and when any offer is carried out.

The dispute has also spilled beyond the regulator. In early August, the São Paulo civil police indicted two Goldman Sachs representatives on suspicion of fraud in an investigation related to the company’s shareholder structure and the failure to carry out the offer; the bank has denied any wrongdoing. Separately, the federal audit court opened an inquiry into potential conflicts of interest involving former CVM directors who later worked for parties linked to the case, and minority investors have filed complaints with the government’s comptroller and the CVM’s own internal affairs office.

Market reaction and what comes next

The decision landed after a week of frenzied trading. As reported by The Rio Times on Monday, Oncoclínicas shares soared 34% ahead of the ruling, and they jumped a further 12.5% on Tuesday morning before the board met. The stock has now risen more than 170% in August, a rally built almost entirely on expectations of the Oncoclínicas tender offer rather than on the company’s results. Analysts caution that once the tender terms are fixed, the shares should converge toward the offer price, leaving limited upside and meaningful downside if the operation stalls.

Attention now turns to the publication of the written vote and to three open questions: the price, the reference date and the universe of shares eligible to participate. Any of these could return to the CVM or end up in arbitration. Centaurus must also show how it would fund a multibillion-real purchase while the target company restructures its own balance sheet. For minority shareholders, the board’s vote converts a two-year legal theory into a regulatory obligation, but the path from this week’s ruling to cash in hand still runs through several more chapters.

Frequently Asked Questions

Sources

• noticias.uol.com.br
• timesbrasil.com.br
• www.estadao.com.br
• valor.globo.com
• www.brasil247.com

This article was produced by The Rio Times’ automated newsroom system. How we use AI · Report an error